Screener
BioCryst Pharmaceuticals BCRX Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Royalty financing obligations | 43,808 | 38,455 |
| Deferred revenue | 12,320 | — |
| Total current liabilities | 208,846 | 196,066 |
| Operating lease liabilities | 10,603 | 8,571 |
| Finance lease liabilities | 849 | 1,441 |
| Royalty financing obligations | 382,981 | 427,233 |
| Secured term loan | 395,400 | — |
| Deferred revenue | 13,461 | — |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's operating lease liabilities?
- BioCryst Pharmaceuticals (BCRX) reported operating lease liabilities of $10.6M in Q2 2026.
- How has BioCryst Pharmaceuticals's operating lease liabilities changed year-over-year?
- BioCryst Pharmaceuticals's operating lease liabilities increased by 24.9% year-over-year, from $8.49M to $10.6M.
- What is the long-term trend for BioCryst Pharmaceuticals's operating lease liabilities?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's operating lease liabilities has grown at a 17.2% compound annual growth rate (CAGR), from $3.87M to $8.57M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about BioCryst Pharmaceuticals's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude